In this review:
The review presents relevant background information on gastro-oesophageal reflux disease (GORD)
and focuses on its management, including pharmacotherapy. In particular, it describes alginate-based
preparations and their place in therapy: as a first-line option in patients with occasional, mild GORD
symptoms, and in pregnancy and breastfeeding; for long term and/or on-demand therapy following the
stepping-down or cessation of proton pump inhibitors (PPIs); and in combination with PPIs for relief of
breakthrough symptoms in PPI-unresponsive GORD. This review is intended as an educational resource for health care professionals and is sponsored by Reckitt Benckiser Ltd.
Download PDF